⌘K

16:17:58·8d

SECFiling

SEC Form DEFA14A filed by Neurocrine Biosciences Inc.

NBIX· Neurocrine Biosciences Inc.

Health Care

Original source

Companies

NBIX
Neurocrine Biosciences Inc.
Health Care

Recent analyst ratings

Feb 24UpdateWolfe Research$160.00
Jan 8UpdateMorgan Stanley$175.00
Oct 21UpdateCitigroup$175.00
Jul 21UpdateTruist$163.00
Jul 10UpdateGoldman$182.00
Apr 15UpdateNeedham$138.00

Related

PR1d
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
SEC8d
SEC Form DEF 14A filed by Neurocrine Biosciences Inc.
PR9d
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
PR9d
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
SEC17d
Neurocrine Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
PR17d
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
SEC27d
Amendment: SEC Form SCHEDULE 13G/A filed by Neurocrine Biosciences Inc.
PR28d
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings